BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Qin HX, Nan KJ, Yang G, Jing Z, Ruan ZP, Li CL, Xu R, Guo H, Sui CG, Wei YC. Expression and clinical significance of TAp73α, p53, PCNA and apoptosis in hepatocellular carcinoma. World J Gastroenterol 2005; 11(18): 2709-2713 [PMID: 15884108 DOI: 10.3748/wjg.v11.i18.2709]
URL: https://www.wjgnet.com/1007-9327/full/v11/i18/2709.htm
Number Citing Articles
1
Jiangbo Liu, Qingyong Ma, Min Zhang, Xinshuai Wang, Dong Zhang, Wei Li, Fengfei Wang, Erxi Wu. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysisEuropean Journal of Cancer 2012; 48(15): 2328 doi: 10.1016/j.ejca.2012.03.001
2
Hina Zafar, Shakir Ali. Boron inhibits the proliferating cell nuclear antigen index, molybdenum containing proteins and ameliorates oxidative stress in hepatocellular carcinomaArchives of Biochemistry and Biophysics 2013; 529(2): 66 doi: 10.1016/j.abb.2012.11.008
3
Ya-nan Ji, Qin Wang, Jun Xue. TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysisTumor Biology 2014; 35(2): 1653 doi: 10.1007/s13277-013-1228-7
4
Zhao-Shan Niu, Xiao-Jun Niu, Mei Wang. Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survivalWorld Journal of Hepatology 2015; 7(1): 7-27 doi: 10.4254/wjh.v7.i1.7
5
Shuangshuang Ma, Junsheng Yang, Jinpeng Li, Jinlong Song. The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinomaTumor Biology 2016; 37(6): 7405 doi: 10.1007/s13277-015-4582-9
6
Christopher D. Mann, Christopher P. Neal, Giuseppe Garcea, Margaret M. Manson, Ashley R. Dennison, David P. Berry. Prognostic molecular markers in hepatocellular carcinoma: A systematic reviewEuropean Journal of Cancer 2007; 43(6): 979 doi: 10.1016/j.ejca.2007.01.004